BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    TECNIS IOL

    MDR report key: 16450298 · Received February 27, 2023

    Report

    Report Number
    3012236936-2023-00505
    Event Type
    Malfunction
    Date Received
    February 27, 2023
    Report Date
    May 15, 2023
    Manufacturer
    AMO PUERTO RICO MFG. INC.
    Product Code
    HQL
    PMA / PMN Number
    P980040
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    PATIENTS' AGE/DATE OF BIRTH: EXACT AGE NOT PROVIDED, STANDARD DEVIATION UNIT OF MEASURE OF YEARS: 66.1 (7.96) PATIENTS' SEX/GENDER: FEMALE 211, MALE 132. PATIENTS' WEIGHT: UNKNOWN/NOT PROVIDED. PATIENTS' RACE: AMERICAN INDIAN OR ALASKA NATIVE 1, ASIAN, 3, NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER 0, BLACK OR AFRICAN AMERICAN 22, WHITE 311, MORE THAN ONE RACE 0, UNKNOWN OR NOT REPORTED 6. PATIENTS' ETHNICITY: HISPANIC OR LATINO 22, NOT HISPANIC OR LATINO 320, UNKNOWN OR NOT REPORTED 1. DATE OF EVENT: 10/24/2022. THE DATE RESULTS POSTED. MODEL NUMBER: PARTIALLY KNOWN, AS THE SERIAL NUMBER WAS NOT PROVIDED. CATALOG NUMBER: A COMPLETE CATALOG NUMBER IS UNKNOWN, AS THE SERIAL NUMBER WAS NOT PROVIDED. SERIAL NUMBER: UNKNOWN, INFORMATION NOT PROVIDED. EXPIRATION DATE: UNKNOWN, AS THE SERIAL NUMBER WAS NOT PROVIDED. UDI NUMBER: UNKNOWN, AS THE SERIAL NUMBER WAS NOT PROVIDED. IF IMPLANTED; GIVE DATE: UNKNOWN/NOT PROVIDED. IF EXPLANTED; GIVE DATE: UNKNOWN/NOT PROVIDED. THE DEVICE WAS NOT RETURNED FOR EVALUATION AND THE SERIAL NUMBER FOR THIS DEVICE IS UNKNOWN/NOT PROVIDED; THEREFORE, NO FURTHER PRODUCT INVESTIGATION CAN BE PERFORMED. SHOULD ANY FURTHER RELEVANT INFORMATION BECOME AVAILABLE A SUPPLEMENTAL MEDWATCH WILL BE FILED. DEVICE MANUFACTURE DATE: UNKNOWN, AS THE SERIAL NUMBER WAS NOT PROVIDED. HEALTH EFFECT - CLINICAL CODE: 4581 - THIS CODE WAS USED FOR THE REPORTED LENS DISLOCATION. CITATION: MICHNA, M. (2018, AUGUST 16 - 2022, OCTOBER 24). CLINICAL EVALUATION OF A SMALL APERTURE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS. IDENTIFIER NCT03633695. HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT03633695. AN ATTEMPT HAS BEEN MADE TO OBTAIN MISSING INFORMATION; HOWEVER, NO DEFINITIVE RESPONSE HAS BEEN RECEIVED. ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.

    Additional Manufacturer Narrative · 0

    CORRECTED DATA: ON (B)(6) 2023, PRODUCT IDENTIFIERS WITH SERIAL NUMBERS (SN) WERE PROVIDED WITH AFFECTED EYES. SEE ATTACHED SPREADSHEET. PER ATTACHED SPREADSHEET THERE WERE NO MALFUNCTION EVENTS FOR THE IOL MODEL ZCB00. THEREFORE, THIS EVENT IS NO LONGER REPORTABLE. NO FURTHER INFORMATION WILL BE PROVIDED UNDER MANUFACTURER REPORT NUMBER 3012236936-2023-00505. BELOW ARE THE MANUFACTURER REPORT NUMBERS RELATED TO THIS LITERATURE ARTICLE: MODEL ZCT150 SERIOUS INJURY REPORT- MANUFACTURER REPORT NUMBER 3012236936-2023-00525. MODEL ZCB00 SERIOUS INJURY REPORT- MANUFACTURER REPORT NUMBER 3012236936-2023-00528. MODEL ZCT225 SERIOUS INJURY REPORT- MANUFACTURER REPORT NUMBER 3012236936-2023-00529. MODEL ZCT150 MALFUNCTION REPORT- MANUFACTURER REPORT NUMBER 3012236936-2023-00504. MODEL ZCB00 MALFUNCTION REPORT- MANUFACTURER REPORT NUMBER 3012236936-2023-00505. MODEL ZCT225 MALFUNCTION REPORT- MANUFACTURER REPORT NUMBER 3012236936-2023-00506. THIS SPECIFIC EVENT WILL CONTINUE TO BE REPORTED UNDER THIS MDR 3012236936-2023-00506. SINCE PRODUCT IDENTIFIERS AND AFFECTED EYES WERE PROVIDED PER THE GUIDANCE GIVEN BY THE FDA MDR POLICY RESPONSE LINE ON 5/5/2023 A NEW MANUFACTURER REPORT NUMBER 3012236936-2023-01227 IS BEING SUBMITTED. ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.

    Description of Event or Problem · 0

    THE FOLLOWING ARTICLE WAS RECEIVED BASED ON LITERATURE REVIEW. ARTICLE: CLINICAL EVALUATION OF A SMALL APERTURE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS. A NONRANDOMIZED INTERVENTIONAL CLINICAL TRIAL WAS DONE TO DETERMINE THE SAFETY AND EFFECTIVENESS OF THE IC-8¿ INTRAOCULAR LENS (IOL) IMPLANTED IN ONE EYE AND A MONOFOCAL OR MONOFOCAL TORIC IOL IMPLANTED IN THE FELLOW EYE IN ACCORDANCE WITH THE INDICATION (CATARACT AND PRESBYOPIA). THERE WERE INITIALLY 548 PATIENTS, 79 OF WHOM WERE CONSIDERED SCREEN FAILURES; LEAVING 469 SUBJECTS WHO WERE PROVISIONALLY ENROLLED WHEREIN 16 PATIENTS WERE DISCONTINUED FROM THE STUDY PRIOR TO SECOND EYE IMPLANTATION. A TOTAL OF 453 PARTICIPANTS WERE SUCCESSFULLY BILATERALLY IMPLANTED IN THE STUDY AND WERE DIVIDED INTO EXPERIMENTAL (CATARACT; N=343 PATIENTS) AND CONTROL (PRESBYOPIA; N=110 PATIENTS) GROUPS. THE EXPERIMENTAL GROUP (N=686 EYES) WERE IMPLANTED WITH A MONOFOCAL IOL (ACRYSOF® IQ SA60WF OR TECNIS® ASPHERIC MONOFOCAL ZCB00, JOHNSON & JOHNSON VISION), OR MONOFOCAL TORIC IOL (ACRYSOF® IQ SA6AT3, SA6AT4 OR TECNIS® ZCT150 OR ZCT225, JOHNSON & JOHNSON VISION) IN THE FIRST EYE AND THE IC-8¿ IOL (ACUSOFT, INC.) IN THE SECOND EYE. THE CONTROL GROUP (N=220 EYES) WERE BILATERALLY IMPLANTED WITH MONOFOCAL IOLS (ACRYSOF® IQ SA60WF OR TECNIS® ASPHERIC MONOFOCAL ZCB00), OR MONOFOCAL TORIC IOLS (ACRYSOF® IQ SA6AT3, SA6AT4 OR TECNIS® ZCT150 OR ZCT225). EACH STUDY GROUP (IC-8¿ IOL GROUP, CONTROL GROUP) WERE ASSIGNED TO ASTIGMATISM GROUP 1 (<1.0 D) OR ASTIGMATISM GROUP 2 (1.0 D - 1.5 D) AS DETERMINED BY PREOPERATIVE CORNEAL ASTIGMATISM IN THE SECOND EYE AS MEASURED BY OPTICAL BIOMETRY. AMONG THESE, ONLY 432 PATIENTS (IC-8¿ IOL GROUP: N=331 PATIENTS, 662 EYES; CONTROL GROUP: N=101 PATIENTS, 202 EYES) COMPLETED THE STUDY. THE 21 PATIENTS WHO DID NOT COMPLETE THE STUDY WERE EITHER DISCONTINUED OR LOST TO FOLLOW-UP. THE GROUPS WERE FURTHER DESCRIBED AS FOLLOWS: ALL SECOND EYES (STUDY EYES) IMPLANTED WITH IC-8¿ IOL IN THE IC-8¿ IOL GROUP (IC-8¿ IOL GROUP - 2ND EYE); ALL FIRST EYES (FELLOW EYES) IMPLANTED WITH AN ACRYSOF® IQ SA60WF OR TECNIS® ASPHERIC MONOFOCAL ZCB00, OR MONOFOCAL TORIC IOL (ACRYSOF® IQ SA6AT3, SA6AT4 OR TECNIS® ZCT150 OR ZCT225) IN THE IC-8¿ IOL GROUP (IC-8¿ IOL GROUP ¿ 1ST EYE OR FELLOW EYES); ALL SUBJECTS IMPLANTED WITH THE IC-8¿ IOL IN THE IC-8¿ IOL GROUP (IC-8¿ IOL GROUP ¿ SYSTEMIC); ALL SECOND EYES IMPLANTED WITH AN ACRYSOF® IQ SA60WF OR TECNIS® ASPHERIC MONOFOCAL ZCB00, OR MONOFOCAL TORIC IOL (ACRYSOF® IQ SA6AT3, SA6AT4 OR TECNIS® ZCT150 OR ZCT225) IN THE CONTROL GROUP (CONTROL GROUP - 2ND EYE); ALL FIRST EYES IMPLANTED WITH AN ACRYSOF® IQ SA60WF OR TECNIS® ASPHERIC MONOFOCAL ZCB00, OR MONOFOCAL TORIC IOL (ACRYSOF® IQ SA6AT3, SA6AT4 OR TECNIS® ZCT150 OR ZCT225) IN THE CONTROL GROUP (CONTROL GROUP ¿ 1ST EYE); AND ALL SUBJECTS IMPLANTED WITH AN ACRYSOF® IQ SA60WF OR TECNIS® ASPHERIC MONOFOCAL ZCB00, OR MONOFOCAL TORIC IOL (ACRYSOF® IQ SA6AT3, SA6AT4 OR TECNIS® ZCT150 OR ZCT225) IN THE CONTROL GROUP (CONTROL GROUP ¿ SYSTEMIC). SERIOUS ADVERSE EVENTS INCLUDED: CYSTOID MACULAR EDEMA (FELLOW EYES, N=4; 1.2%; CONTROL ¿ 2ND EYE, N= 0.91%) AND IRIS INJURY (CONTROL ¿ 2ND EYE, 0.91%). POSTOPERATIVE SURGICAL INTERVENTIONS FOR THE OCULAR ADVERSE EVENTS INCLUDED: INTRAVITREAL INJECTION (FELLOW EYES, N=1, 0.3%; CONTROL ¿ 1ST EYE, N=1, 0.9%), IOL EXCHANGE (CONTROL ¿ 2ND EYE, N=1, 0.9%; CONTROL ¿ 1ST EYE, N=1, 0.9%), IOL REPOSITIONING (FELLOW EYES, N=1, 0.3%; CONTROL ¿ 1ST EYE, N=1, 0.9%), IRIS REPOSITION (CONTROL ¿ 1ST EYE, N=1, 0.9%), LASER RETINOPEXY (FELLOW EYES, N=1, 0.3%), LASER VITREOLYSIS (CONTROL ¿ 2ND EYE, N=1, 0.9%), MODIFIED PARACENTESIS (FELLOW EYES, N=3, 0.9%; CONTROL ¿ 1ST EYE, N=1, 0.9%), AND VITRECTOMY (FELLOW EYES, N=1, 0.3%). PERSISTENT OCULAR SERIOUS ADVERSE EVENTS IN FELLOW EYES WERE: CYSTOID MACULAR EDEMA (N=1, 0.3%) AND IRITIS (N=1, 0.3%). OTHER POSTOPERATIVE SERIOUS AND NON-SERIOUS OCULAR ADVERSE EVENTS RELATED TO DEVICE WERE: POSTERIOR CAPSULE OPACIFICATION (FELLOW EYES, N=1, 0.3%), ALTERED VISUAL DEPTH PERCEPTION (FELLOW EYES, N=1, 0.3%), DYSPHOTOPSIA (FELLOW EYES, N=3, 0.9%; CONTROL GROUP ¿ 1ST EYE, N=1, 0.9%) AND VISION BLURRED (FELLOW EYES, N=1, 0.3%). OTHER LISTED NONSERIOUS ADVERSE EVENTS INCLUDED: CATARACT OPERATION COMPLICATION, LENS DISLOCATION (FELLOW EYES, N=1; CONTROL GROUP ¿ 1ST EYE, N=1), CILIARY ZONULAR DEHISCENCE, VITREOUS PROLAPSE (CONTROL GROUP ¿ 1ST EYE, N=1), CONJUNCTIVAL EDEMA (FELLOW EYES, N=1), CONJUNCTIVAL HEMORRHAGE (FELLOW EYES, N=3), CONJUNCTIVAL ABRASION (CONTROL GROUP - 2ND EYE, N=1), CONJUNCTIVITIS (FELLOW EYES, N=4; CONTROL GROUP - 2ND EYE, N=2; CONTROL GROUP ¿ 1ST EYE, N=1), CORNEAL ABRASION (CONTROL GROUP - 2ND EYE, N=2; CONTROL GROUP ¿ 1ST EYE, N=2), CORNEAL DEPOSITS, CORNEA VERTICILLATA (FELLOW EYES, N=1), CORNEAL DYSTROPHY (FELLOW EYES, N=3), CORNEAL EPITHELIAL MICROCYSTS (FELLOW EYES, N=1), CORNEAL STROMAL EDEMA (CONTROL GROUP - 2ND EYE, N=1), CYSTOID MACULAR EDEMA (FELLOW EYES, N=3; CONTROL GROUP ¿ 1ST EYE, N=1), DACRYOSTENOSIS ACQUIRED (FELLOW EYES, N=1), DETACHMENT OF RETINAL PIGMENT EPITHELIUM, RETINAL DEPIGMENTATION (CONTROL GROUP ¿ 2ND EYE, N=1; CONTROL GROUP ¿ 1ST EYE, N=1), DIPLOPIA (FELLOW EYES, N=2), DRY EYE (FELLOW EYES, N=26; CONTROL GROUP ¿ 2ND EYE, N=9; CONTROL GROUP ¿ 1ST EYE, N=9), DYSPHOTOPSIA (FELLOW EYES, N=3; CONTROL GROUP ¿ 2ND EYE, N=1; CONTROL GROUP ¿ 1ST EYE, N=2), EYE IRRITATION (FELLOW EYES, N=1; CONTROL GROUP ¿ 2ND EYE, N=1), EYE PAIN (FELLOW EYES, N=1; CONTROL GROUP ¿ 2ND EYE, N=1; CONTROL GROUP ¿ 1ST EYE, N=1), EYE PRURITUS (FELLOW EYES, N=2), EYELID INFECTION (FELLOW EYES, N=2), FOREIGN BODY IN EYE (FELLOW EYES, N=1), INTRAOCULAR PRESSURE INCREASED (FELLOW EYES, N=16; CONTROL GROUP ¿ 2ND EYE, N=10; CONTROL GROUP ¿ 1ST EYE, N=7), IRITIS (FELLOW EYES, N=7; CONTROL GROUP ¿ 2ND EYE, N=5; CONTROL GROUP ¿ 1ST EYE, N=2), KERATIC PRECIPITATES (FELLOW EYES, N=1), OCULAR DISCOMFORT (FELLOW EYES, N=1), PHOTOPHOBIA (FELLOW EYES, N=1), POSTERIOR VITREOUS DETACHMENT (FELLOW EYES, N=8; CONTROL GROUP ¿ 1ST EYE, N=4), POSTERIOR CAPSULE OPACIFICATION (FELLOW EYES, N=48; CONTROL GROUP ¿ 2ND EYE, N=19; CONTROL GROUP ¿ 1ST EYE, N=1), POSTERIOR CAPSULE TEAR (CONTROL GROUP ¿ 2ND EYE, N=1; CONTROL GROUP ¿ 1ST EYE, N=1), PUNCTATE KERATITIS (FELLOW EYES, N=1; CONTROL GROUP ¿ 2ND EYE, N=3; CONTROL GROUP ¿ 1ST EYE, N=2), RETINAL DRUSEN (CONTROL GROUP ¿ 2ND EYE, N=1; CONTROL GROUP ¿ 1ST EYE, N=1), RETINAL TEAR (FELLOW EYES, N=1), RETINAL VEIN OCCLUSION (FELLOW EYES, N=1), UVEITIS (INTERMEDIATE) (FELLOW EYES, N=1), VISION BLURRED (FELLOW EYES, N=3), VISUAL ACUITY REDUCED (FELLOW EYES, N=1) AND VITREORETINAL TRACTION SYNDROME (CONTROL GROUP ¿ 1ST EYE, N=1). THERE WERE NO FURTHER INTERVENTIONS REPORTED. IT IS UNCLEAR IF THE COMPLAINTS REPORTED WERE CAUSED BY THE J&J DEVICES OR THE OTHER DEVICES USED IN THE STUDY. A COPY OF THE ARTICLE IS PROVIDED WITH THIS REPORT. THIS REPORT IS FOR MODEL ZCB00 MALFUNCTION EVENT. SEPARATE REPORTS ARE BEING SUBMITTED TO CAPTURE THE MALFUNCTION EVENT FOR MODEL ZCT225 AND MODEL ZCT150. SEPARATE REPORTS ARE ALSO BEING SUBMITTED TO CAPTURE THE ADVERSE EVENTS FOR MODELS ZCT150, ZCT225, AND MODEL ZCB00.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    752302 TECNIS IOL INTRAOCULAR LENS HQL AMO PUERTO RICO MFG. INC. ZCB00

    Patients

    Seq Age Sex Outcome Treatment
    1 Unknown